JDD Buzz Series | GLP-1 Agonists for Hidradenitis Suppurativa
GLP-1 receptor agonists are revolutionizing the treatment of type 2 diabetes and obesity. With widespread consumer advertising campaigns, GLP-1 usage is becoming commonplace. National polls show up to one-fifth of American adults have tried GLP-1s for weight loss or to address health conditions, such as heart disease. As the understanding of GLP-1s deepens, so does their potential. Since recent re …
GLP-1 receptor agonists are revolutionizing the treatment of type 2 diabetes and obesity. With widespread consumer advertising campaigns, GLP-1 usage is becoming commonplace. National polls show up to one-fifth of American adults have tried GLP-1s for weight loss or to address health conditions, such as heart disease. As the understanding of GLP-1s deepens, so does their potential. Since recent re … Continue reading "JDD Buzz Series | GLP-1 Agonists for Hidradenitis Suppurativa"
Welcome to “JDD September 2025 Issue Highlights,” your guided tour through this month’s must-read studies, curated by the Journal of Drugs in Dermatology Editorial Team. This issue features a Special Focus on Aesthetic Treatments alongside cutting-edge research in novel pharmacotherapies, advanced procedural techniques, and safety assessments. Whether you’re dialing in volumization with po …